Amgen Inc.

Biogen Ma Inc.

Cytokinetics, Inc.

Felix Gonzalez Lopez De Turiso

Timothy David Cushing

Michael G Johnson

Jason A Duquette

Xiaolin Hao

Xuelei Yan

Yi Heng Chen

Lawrence R McGee

Daqing Sun

Yosup Rew

Youngsook Shin

Xiao He

Julio Cesar Medina

Alan C Cheng

Brian Stuart Lucas

Jennifer L Seganish

Bradley Paul Morgan

Frank Kayser

Robert Michael Rzasa

Chihyuan Chuang

Luke W Ashcraft

Dawei Zhang

Scott E Collibee

Brian M Fox

Michael D Bartberger

Russell Graceffa

Hilary Plake Beck

Alessandro Boezio

Ana Zurisadai Gonzalez Buenrostro

Steven H Olson

Mikkel V Debenedetto

Andreas Reichelt

Zhihong Li

Brian Gregory Lucas

Antonio Romero

David Joseph St Jean, Jr

Richard Vargas

David C Moebius

Jiasheng Fu

Joshua Payette

John R Butler

Philip M Roveto

Aroop Chandra

Justin Malinowski

Hanmo Zhang

Vincent DiMassa

Xiaoqi Chen

Zhili Xin

Xiaodong Wang

Jeffrey Thomas Mihalic

Dustin L McMinn

Zhihua Ma

Ming Yu

David John Kopecky

John Eksterowicz

John Howard Jones

Richard V Connors

Jeffrey Deignan

Julie Anne Heath

Darin J Gustin

Yingcai Wang

Joel McIntosh

Minna Bui

Todd J Kohn

Michael R Degraffenreid

Yihong Li

Michael W Gribble, Jr

Benjamin Fisher

Jiang Zhu

Lisa D Julian

Jay Patrick Powers

Zice Fu

Jonathan Dante Low

Jiwen Liu

Vatee Pattaropong

XianYun Jiao

Michael A Dechantsreiter

Xin Huang

SuJen Lai

Jonathan B Houze

Michael Luzzio

Matthew Irvine Brown

Liusheng Zhu

Paul John Dransfield

Sean P Brown

Xianghong Wang

Zhulun Wang

Mario G Cardozo

Kexue Li

Mike Elias Lizarzaburu

Marc Vimolratana

Yunxiao Li

Michael J Schmitt

Jacob A Kaizerman

Xian Yun Jiao

Julia Winslow Lohman

Manuel Zancanella

Joshua Taygerly

Provided are compounds of Formula (I): including compounds of Formulas (II), (III) and (IV), wherein X, R, R, Rand n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).

ASK1 inhibiting agents

Provided are compounds of Formula (I): Formula (I), including compounds of Formulas (II), (III), (IV), (V) and (VI), wherein X, R, R, R, Rand n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).

Provided are compounds of Formula (I′), including compounds of Formulas (I), (II), (III), (IIIA) and (IIIB), wherein L, R, Rand n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).

Pyridine macrocycle compounds as ASK1 inhibiting agents

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

Bisamide sarcomere activating compounds and uses thereof

The present invention provides MDM2 inhibitor compounds of Formula I, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Compounds that inhibit MCL-1 protein

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof. 

Provided are compounds of Formulas (I'), (I), (II&#x2032;) and (II), or pharmaceutically acceptable salts thereof, and methods for their use and production.

Bisamide sarcomere activating compounds and uses therof

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110&#x3b4; activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

Heterocyclic compounds and their uses

The present invention provides MDM2 inhibitor compounds of Formula I, 

Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer

The present invention provides MDM2 inhibitor compounds of Formula I or II, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer

Growing community of inventors

San Mateo, CA, United States of America

Felix Gonzalez Lopez De Turiso